

AJOVY[®]
(fremanezumab)
injection 225 mg/1.5 mL

AJOVY[®] (fremanezumab)

Momentum Program

A Pharmacist's guide

For patients with an AJOVY private prescription

Updated August 2024

The AJOVY Momentum Program aims to improve the value, outcomes and support available to adults prescribed AJOVY for the prevention of migraines. This program is only available to patients with a private prescription for AJOVY, and aims to enable patient access at a special (reduced) price, via a program subsidised by TEVA Pharma Australia.

This leaflet contains important information about the AJOVY Momentum Program and how to facilitate special-price AJOVY access for patients with a private prescription. Please read it carefully and follow the instructions for entering AJOVY patient orders.



Managing your patient on the AJOVY® Momentum Program

What is the Momentum Program?

- The Momentum Program has been running for several years in a different format. It enables patient access to AJOVY at a reduced price, subsidised by the manufacturer, TEVA Pharma Pty Ltd. Recently TEVA has broadened its availability for the benefit of patients and their preferred Pharmacies

Why have you been given this brochure?

- The process for ordering, supplying and charging a patient via this program is different from the usual PBS or non-Momentum private dispensing. Upon presenting with a private prescription, the Pharmacist will be responsible for order entry and the special payment process for the patients. This brochure describes the straightforward process and tools to achieve this

Pharmacists Australia-wide are enabling this access

- By facilitating the supply of AJOVY via this program, Pharmacists are enabling improved access to AJOVY to migraine patients. Each dispensing also includes a dispensing fee to Pharmacy

What's the process for the AJOVY Momentum Program?

The AJOVY[®] Momentum Program Process

- 1** • Doctor prescribes an AJOVY private script for a patient that is ineligible for a PBS script
- 2** • Doctor advises the patient that they will expect to pay \$299 for a single unit of AJOVY via a private script under the TEVA Momentum Program (or for a quarterly dosing prescription, a price of \$897 for three AJOVY units)
- 3** • Patient presents the prescription and this booklet to the Pharmacist for processing and ordering via the online Momentum portal
- 4** • Order is received and placed with chosen wholesaler, AJOVY is shipped to Pharmacy at Momentum cost

Note: Although usual delivery of AJOVY is 2-3 business days, TEVA is not responsible for deliveries ex-wholesaler

Fulfilling the Patient Order

AJOVY[®]
(fremanezumab)
injection 225 mg/1.5 mL

1

- Upon presentation of the patient and prescription, using a QR code or web link (see below), the Pharmacist is directed to a dedicated Momentum ordering webpage ("AJOVY ordering portal")

2

- The online ordering process includes a confirmation that the patient will receive AJOVY at the special pricing for either monthly or quarterly dosing, of \$299 or \$897 respectively
- These prices include a \$20 (single unit) or 3 x \$20 (three units) dispensing fee to the Pharmacy

3

- Pharmacist submits the required patient and product information into the portal
- An email confirmation of the order will follow

4

- Order is received by TEVA for processing and ordering commences with nominated wholesaler, for delivery within 2-3 business days

5

- Pharmacist supplies the AJOVY to the patient at the special price

NB: This process above occurs at every presentation of the patient for each subsequent supply of AJOVY

Scan the QR code or click here for the link to the AJOVY Momentum Ordering Portal:
<https://ajovy.mmw3degrees.com.au>



AJOVY® Momentum Ordering Portal



The following screenshots illustrate the 4 steps involved in placing a Momentum Order:

1. Login (Pharmacist email and AHPRA number)

2. Pharmacist Order History

Email Address	AHPRA Number	Order Date	Wholesaler Name	Priority Date	Status
pharmacist@teva.com	12345678901234	15/01/2023	TEVA PHARMA	2023-01-15 10:00	Completed
pharmacist@teva.com	12345678901234	16/01/2023	TEVA PHARMA	2023-01-16 10:00	Completed
pharmacist@teva.com	12345678901234	17/01/2023	TEVA PHARMA	2023-01-17 10:00	Completed
pharmacist@teva.com	12345678901234	18/01/2023	TEVA PHARMA	2023-01-18 10:00	Completed
pharmacist@teva.com	12345678901234	19/01/2023	TEVA PHARMA	2023-01-19 10:00	Completed
pharmacist@teva.com	12345678901234	20/01/2023	TEVA PHARMA	2023-01-20 10:00	Completed
pharmacist@teva.com	12345678901234	21/01/2023	TEVA PHARMA	2023-01-21 10:00	Completed
pharmacist@teva.com	12345678901234	22/01/2023	TEVA PHARMA	2023-01-22 10:00	Completed
pharmacist@teva.com	12345678901234	23/01/2023	TEVA PHARMA	2023-01-23 10:00	Completed
pharmacist@teva.com	12345678901234	24/01/2023	TEVA PHARMA	2023-01-24 10:00	Completed
pharmacist@teva.com	12345678901234	25/01/2023	TEVA PHARMA	2023-01-25 10:00	Completed

3. Order Entry Screen

4. Order Confirmation Screen

Additional program information

The AJOVY Momentum Program is sponsored by TEVA Pharma Australia Pty Ltd. TEVA has the right to cease or change this program at any time. Reasonable notice will be provided in advance of any changes to the AJOVY Momentum Program

Program contact details

For any questions regarding this program, the ordering process or issues with the ordering portal, contact TEVA Australia Customer Service on 02 8061 9928 or email customerservice.au@tevapharm.com

Medical Information contact details

If you have any questions or concerns about the patient's treatment, adverse events or their handling of the injection devices, please contact their prescribing doctor and/or TEVA medical information on 1800 AU TEVA (1800 28 8382) or email MedInfo.ANZ@tevapharm.com

PBS Information: Authority required (STREAMLINED) for treatment-resistant migraine.
This product is not listed on the PBS for quarterly dosing.

PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.

The Product Information can be accessed at <https://rss.medsinfo.com.au/tb/pi.cfm?product=tbpajovy> or from Medical Information on 1800 AU TEVA (1800 28 8382).

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

MINIMUM PRODUCT INFORMATION: Ajovy® (fremanezumab) 225 mg/1.5mL solution for injection in a pre-filled syringe and 225 mg/1.5mL solution for injection in an autoinjector. **Indication:** preventive treatment of migraine in adults. **Contraindications:** Hypersensitivity to the active substance or to any other component of the product. **Precautions:** *Hypersensitivity*; consider discontinuation and initiate appropriate treatment. *Major Cardiovascular Disease*; some patient groups with major cardiovascular disease were excluded from clinical trials. No safety data is available in these patients. No data available in elderly or paediatric patients. No data available in renal or hepatic impairment. See Full PI. *Pregnancy* Category B1; may cross placenta. *Lactation*; unknown whether fremanezumab is excreted in human milk. No or negligible influence on the ability to drive or operate machinery. **Interactions:** No formal clinical drug interaction studies have been performed. *Concomitant Migraine Treatment*; concomitant use of acute migraine treatments (analgesics, ergots and triptans) and preventive migraine medications did not influence safety and efficacy. *CYP450 Substrates*; pharmacokinetic interactions are not expected when co-administered. See Full PI. **Adverse Effects:** *Clinical Trials*; **Very Common:** Injection site pain, injection site induration, injection site erythema. **Common:** Injection site pruritus. Reactions were mild to moderate. *Immunogenicity*; no significant adverse events related to Anti-Drug Antibodies (ADA) have been reported. Safety and efficacy were not affected by ADA development. See Full PI. *Post-marketing reports*; **Uncommon:** Hypersensitivity reactions such as rash, pruritus, urticaria and swelling. **Rare:** Anaphylactic reaction. **Dosage and Administration:** Treatment should be initiated by a physician experienced in the diagnosis and treatment of migraine. Must **only** be administered by **subcutaneous injection**. Available in a **monthly dose**; 225 mg once monthly or a **quarterly dose**; 675 mg every three months. *Switching Dose Regimens*; first dose of the new regimen should be administered on the next scheduled dose date of the prior regimen. See Full PI. **Instructions for use:** Remove from the refrigerator and allow to reach room temperature for 30 minutes prior to use. Do **not** use if it has been stored unrefrigerated for longer than 7 days, or at temperatures higher than 30°C. The pre-filled syringe and autoinjector should **not** be shaken. Visually inspect for particles or discolouration prior to administration. AJOVY is a clear to opalescent, colourless to slightly yellow solution. Do **not** use if the solution is cloudy, discoloured, or contains particles. Do **not** use if AJOVY is frozen. See Full PI. **Presentation:** 1.5 mL solution in a 2.25 mL glass syringe; or autoinjector containing an integrated 1.5 mL solution in a 2.25 mL glass syringe. Pack sizes of one 225mg/1.5mL or three 225mg/1.5mL pre-filled syringes or autoinjectors. **Storage:** Store in a refrigerator (2°C to 8°C). Do **not** freeze. Store in the original carton in order to protect from light. May be stored unrefrigerated for up to 7 days at a temperature up to 30°C. Must be discarded if not used within 7 days of removal from refrigeration. Based on Product Information approved 31 May 2024. Date of minimum PI preparation: 17 June 2024. **PLEASE REVIEW PRODUCT INFORMATION BEFORE PRESCRIBING.** The Product Information can be accessed at <https://rss.medsinfo.com.au/tb/pi.cfm?product=tbpajovy> or from Medical Information on 1800 AU TEVA (1800 28 8382). Sponsored in Australia by TEVA Pharma Australia Pty Ltd, ABN 41 169 715 664, Level 1, 37 Epping Road, Macquarie Park, Sydney, NSW 2113.

AJOVY® is a registered trademark of TEVA Pharmaceutical Industries Ltd.
TEVA Pharma Australia Pty Ltd, ABN 41 169 715 664, Level 1, 37 Epping Road,
Macquarie Park, Sydney, NSW 2113. Phone: 1800 AU TEVA (1800 28 8382).
Fax: +61 2 8061 9999. www.tevapharma.com.au. Date of preparation: August 2024.
AJO-AU-00059. Date of expiration: August 2026

The logo for TEVA, featuring the word "teva" in a lowercase, sans-serif font. The letter "v" is stylized with a green leaf-like shape extending from its top right corner.